BiPar Sciences raises $35M
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
BiPar Sciences
|
$35M
|
Domain Associates |
BiPar is developing multiple compounds designed to inhibit PARP 1, an enzyme that is crucial to cell repair and upregulated in certain tumors. |
|
VentiRx Pharmaceuticals
|
$26.6M
|
Frazier Healthcare Ventures, Arch Venture Partners and Domain Associates |
VentiRx Pharmaceuticals was founded by former Anadys' vice president Michael Kamdar and former Dendreon chief medical officer Robert Hershberg. |
|
Advanced BioHealing
|
$25.5M
|
Safeguard Scientifics |
The company plans to spend much of the money advancing its bioengineered wound healing therapies. Safeguard Scientifics led the round. |
|
Calistoga Pharmaceuticals
|
$21M
|
Frazier Healthcare Ventures |
Calistoga will focus on developing therapies for oncology and inflammation. |
|
Trius Therapeutics
|
$20M
|
Sofinnova Ventures |
Trius is developing antibacterial drugs for the treatment of serious infections. |
|
Cara Therapeutics
|
$5M
|
Widows Investment Partnership and Mitsubishi International Corporation |
Cara Therapeutics has secured an additional $5 million in funding to complete its $24 million Series C financing. The first tranche of $19 million closed in November 2006. |